Diamond Biofund (鑽石生技投資股份有限公司) 2024 Q3 Earnings Conference Call

Company Overview

Diamond Biofund (鑽石生技投資股份有限公司) is a venture capital firm focused on biotechnology investments. The company's mission is to become an international biotechnology venture capital firm, building a platform for value creation.

Financial Highlights

The company's financial highlights include:

• Operating revenue of (864,431) NTD Thousand in 2024 Q1-Q2
• Net income (loss) after tax of (941,317) NTD Thousand in 2024 Q1-Q2
• Earnings per share (EPS) of (1.11) NTD in 2024 Q1-Q2

Business Segments

The company's business segments include:

• New drug R&D
• Cell therapy, gene therapy, and drug delivery platforms
• Advanced medical devices, laboratory equipment, agricultural biotechnology, and others

Products & Technologies

The company's products and technologies include:

• ON101 (糖尿病足傷口治療新藥 / New drug for diabetic foot ulcers)
• SNS812 (新冠核酸藥物 / COVID-19 nucleic acid drug)
• FB825 (中重度異位性皮膚炎抗體藥 / Antibody drug for moderate to severe atopic dermatitis)
• SNS851 (創新減重核酸新藥 / Innovative weight-loss nucleic acid drug)

Clients & Markets

The company's clients and markets include:

• Taiwan
• United States
• Europe
• Asia

ESG / Sustainability

The company is committed to environmental, social, and governance (ESG) principles and has published a sustainability report.

Outlook & Strategy

The company's outlook and strategy include:

• Continuously introducing external capital to expand asset management scale
• Seeking investment targets with international competitiveness
• Transforming cutting-edge technology to lead the sustainable development of investment targets
• Attracting outstanding talent to strengthen Diamond Biofund's investment capabilities

Additional Data

Additional data includes:

• Market capitalization of biotechnology and medical industry listed on Taiwan Stock Exchange
• Taiwan Biotechnology Index
• Number of new biotechnology and medical stocks listed on main board, OTC, and emerging stock markets in Taiwan

Investment Portfolio

The company's investment portfolio includes:

• ONENESS (合一生技股份有限公司)
• STEMCYTE (永笙生技)
• Rejuvenate Bio
• Bilayer Therapeutics
• Original BioMedicals
• Theia (晶祈生技)
• EyeYon MEDICAL
• Syncell (新析生技)
• TTT (地天泰農業生技)
• KCP Fund I (美國基金)
• Diamond High-Tech (鑽石高新)
• Diamond No. 1 (鑽石一號)